Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

ALLERGY AND ASTHMA PROCEEDINGS, published by Ocean Side Publications Inc, is a vital resource in the fields of Immunology, Allergy, and Pulmonary Medicine. With an impressive trajectory of publication from 1996 to 2024, this journal serves as a platform for cutting-edge research and advancements in the understanding of allergic and asthmatic conditions. Positioned in the Q3 quartile for Immunology and Allergy and Q2 for both Medicine (miscellaneous) and Pulmonary Medicine, the journal exhibits a robust impact within the academic community, boasting Scopus rankings that reflect its significance. The journal offers open access options, allowing for the dissemination of critical findings to a wider audience. Aimed at researchers, healthcare professionals, and students alike, ALLERGY AND ASTHMA PROCEEDINGS addresses the complexities of respiratory diseases and facilitates the sharing of knowledge that is essential to improving patient care and outcomes.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY is a premier peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the fields of allergy, asthma, and immunology. With its roots dating back to 1995 and with a focus on high-impact research, this journal has established itself as a leading platform for the dissemination of original research, reviews, and clinical studies within these critical areas. The journal boasts an impressive impact factor, supporting its Q2 ranking in both Immunology and Allergy, as well as in Pulmonary and Respiratory Medicine, indicating its significant contribution to the scientific community. Although it does not currently offer open access options, its comprehensive coverage and rigorous peer-review process ensure that published articles are of the highest quality, making it an invaluable resource for researchers, clinicians, and students alike. The Scopus rankings reflect its esteemed position in the academic landscape, providing professionals with access to cutting-edge developments and insights into the management and treatment of allergic and respiratory conditions.

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

Allergy Asthma & Immunology Research, published by the Korean Academy of Asthma Allergy & Clinical Immunology, is a leading journal dedicated to advancing the fields of immunology, allergy, and respiratory medicine. With an ISSN of 2092-7355 and an E-ISSN of 2092-7363, this esteemed publication has been a cornerstone for researchers and practitioners since its inception in 2009 and continues to disseminate critical findings through till 2024. The journal is ranked in the Q3 category in Immunology and the Q2 category in Immunology and Allergy as well as Pulmonary and Respiratory Medicine, illustrating its impact in these vital fields. With a solid Scopus ranking in multiple sub-disciplines, the journal not only contributes to the scientific discourse but also promotes innovative research and clinical practices. Although currently operating without an open access model, the journal remains highly regarded for its thorough peer-review process and commitment to academic excellence, making it an essential resource for professionals, researchers, and students passionate about advancing knowledge in allergy, asthma, and immunology.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.